PT Kimia Farma TbkISX:KAEF -2.15%56 EBITDA Margin % is 13.59% as of Mar. 2026, which is 71% above its 10-year median of 7.96. GuruFocus rates ISX:KAEF with a GF Score™ of 56/100 and a GF Value™ of Rp581.98 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 119 Medical Distribution companies, PT Kimia Farma Tbk ranks better than 66.39% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PT Kimia Farma Tbk's EBITDA for the
three
months ended in Mar. 2026 was Rp275,959 Mil. PT Kimia Farma Tbk's Revenue for the
three
months ended in Mar. 2026 was Rp2,030,649 Mil. Therefore, PT Kimia Farma Tbk's EBITDA margin for the quarter that ended in Mar. 2026 was 13.59%.
PT Kimia Farma Tbk (ISX:KAEF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Kimia Farma Tbk EBITDA Margin % Related Terms
PT Kimia Farma Tbk EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PT Kimia Farma Tbk's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:KAEF vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, PT Kimia Farma Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Tbk EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Tbk (ISX:KAEF) has a EBITDA Margin % of 13.59% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Kimia Farma Tbk and its competitors. This is 71% above median its historical median of 7.96. According to the industry distribution chart, PT Kimia Farma Tbk ranks #40 out of 119 companies in the Medical Distribution industry, placing it in the top 33.6%.
Is PT Kimia Farma Tbk's EBITDA Margin % too high?
PT Kimia Farma Tbk's current EBITDA Margin % of 13.59% is 71% above median its 10-year median of 7.96. The Medical Distribution industry median EBITDA Margin % is 4.31. PT Kimia Farma Tbk's value of 13.59% is 215.3% above this industry median. Based on the distribution chart, PT Kimia Farma Tbk ranks #40 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, PT Kimia Farma Tbk has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Tbk's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Tbk ranks #40 out of 119 companies for EBITDA Margin %. This puts PT Kimia Farma Tbk in the upper half of its industry. The industry median EBITDA Margin % is 4.31. PT Kimia Farma Tbk's value of 13.59% is 215.3% above this benchmark. While the company's 10-year median is 7.96 vs. the industry median of 4.31, PT Kimia Farma Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Tbk's current EBITDA Margin % of 13.59% is 215.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Kimia Farma Tbk and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Tbk's current EBITDA Margin % is 13.59%, which is 71% above median its own 10-year median of 7.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp581.98, compared to a current price of Rp456.00 — trading 21.6% below its estimated fair value. The current EBITDA Margin % is 13.59%, which is 71% above median its 10-year median of 7.96 and 215.3% above the Medical Distribution industry median of 4.31. PT Kimia Farma Tbk's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Kimia Farma Tbk (ISX:KAEF), the current EBITDA Margin % is 13.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Tbk stock appears to be undervalued.
The current stock price of Rp456.00 is trading 21.6% below its estimated GF Value™ of Rp581.98.
GuruFocus considers PT Kimia Farma Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
EBITDA Margin %: 13.59% (71% above median its 10-year median of 7.96)
GF Value™: Rp581.98 vs. price of Rp456.00 (21.6% below fair value)
Industry Position: 215.3% above the Medical Distribution median (#40 of 119)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
56GF Score
Get the complete analysis for ISX:KAEF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
